We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Frontier Ip Group Plc | LSE:FIPP | London | Ordinary Share | GB00B63PS212 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 43.50 | 84,703 | 07:33:18 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 42.00 | 45.00 | 43.50 | 43.50 | 43.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Real Estate Agents & Mgrs | 372k | -3.24M | -0.0580 | -7.50 | 24.32M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:36:36 | O | 11,000 | 42.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/4/2024 | 13:59 | UK RNS | Frontier IP Group plc Holding(s) in Company |
| 12/4/2024 | 09:53 | ALNC |  Frontier IP hires former Argentex CFO Jo Stent as new finance chief |
| 12/4/2024 | 07:00 | UK RNS | Frontier IP Group plc Appointment of Chief Financial Officer |
| 02/4/2024 | 12:44 | UK RNS | Frontier IP Group plc Holding(s) in Company |
| 14/3/2024 | 20:56 | ALNC | EARNINGS AND TRADING: Castillo losses double; GCP proposes wind-down |
| 14/3/2024 | 07:00 | UK RNS | Frontier IP Group plc Unaudited Half Year Results |
| 04/3/2024 | 13:40 | UK RNS | Frontier IP Group plc Holding(s) in Company |
| 29/2/2024 | 18:52 | ALNC | EARNINGS AND TRADING: Frontier IP sells last of Exscientia holding |
| 29/2/2024 | 15:12 | UK RNS | Frontier IP Group plc Sale of shares in Exscientia |
| 30/1/2024 | 11:45 | UK RNS | Frontier IP Group plc Holding(s) in Company |
Frontier Ip (FIPP) Share Charts1 Year Frontier Ip Chart |
|
1 Month Frontier Ip Chart |
Intraday Frontier Ip Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/4/2024 | 11:10 | Frontier IP | 678 |
| 30/7/2011 | 23:11 | Why have they bothered | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-25 14:36:37 | 42.00 | 11,000 | 4,620.00 | O |
| 2024-04-25 14:36:05 | 42.06 | 11,000 | 4,626.60 | O |
| 2024-04-25 14:28:45 | 42.47 | 9,000 | 3,822.30 | O |
| 2024-04-25 14:28:13 | 42.47 | 9,000 | 3,822.30 | O |
| 2024-04-25 14:08:17 | 42.47 | 5,392 | 2,289.80 | O |
| Top Posts |
|---|
Posted at 25/4/2024 09:20 by Frontier Ip Daily Update Frontier Ip Group Plc is listed in the Real Estate Agents & Mgrs sector of the London Stock Exchange with ticker FIPP. The last closing price for Frontier Ip was 43.50p.Frontier Ip currently has 55,916,946 shares in issue. The market capitalisation of Frontier Ip is £24,323,872. Frontier Ip has a price to earnings ratio (PE ratio) of -7.50. This morning FIPP shares opened at 43.50p |
Posted at 05/4/2024 13:27 by aqc888 I fear the share price won’t improve here till the first ipo is announced… which shouldn’t be so long hopefully! |
Posted at 21/3/2024 21:25 by aqc888 It’s been a long hard slog for Neil Crabb, no wonder he’s so dismayed at the current share price being near all time lows, when the portfolio is reaching its most exciting phase. |
Posted at 21/3/2024 21:18 by aqc888 The ceo seemed to be genuinely incredulous at the end regarding the current share price, while pointing out that investors should focus on what people within the trade sectors of portfolio companies are saying, as an indication of what to expect. I have to say he is my favourite ceo of any company I invest in. |
Posted at 18/3/2024 11:54 by rivaldo FIPP are featured on i.i.i as an AIM growth share to consider:"Frontier IP (FIPP) Price: 42p Technology investment company Frontier IP Group FIPP is different to the other companies because if it makes a profit it tends to be because of gains in its portfolio company valuations or those realised via disposals. Management’s relationships with a number of universities in the UK and Portugal provide it with opportunities. There are parts of the portfolio that are starting to mature and provide exits. The model is that Frontier IP earns stakes in technology spin-outs in return for providing advice and services and not from investing cash directly. In the six months to December 2023, the net asset value (NAV) increased from 81.8p/share to 84.2p/share thanks to higher portfolio valuations and a sale of Exscientia shares. Nasdaq listed investee company Exscientia is an example of the potential for gains, although not all early-stage portfolio investments will do well. Exscientia is a spin-out from the University of Dundee and uses artificial intelligence to help drug discovery. Frontier IP has raised £14 million from share sales, whereas the cost of the investment was less than £2,000. Another investee company Alusid, a spin-out from the University of Central Lancashire, produces sustainable tiles and could be on course for a flotation. Other investee companies are making progress with Heriot Watt University spin-out Nandi Proteins singing a commercial licence with a global food ingredients company. There was cash of £2.7 million at the end of 2023, while a further £1.7 million was subsequently raised from selling the remaining Exscientia shares. There has been a sharp recovery in the share price this year, but it is still 45% lower than at the end of 2022. The 50% discount to NAV partially reflects the fact that the portfolio is predominantly unquoted. Even so, this discount is too high and should narrow, while positive news on Alucid could provide further upside." |
Posted at 07/3/2024 08:00 by hastings Good catch up with the CEO yesterday and I plan to meet up with him after the Interim's in a couple of weeks time. So, I'll add my write up after that as there should be more to say then, as effectively in a closed period. For now, Nandi very much alive, but news dictated by commerciality agreements. A number of investments appear to be nearing key points, so there should be more on the news front through the year. Institutional sells down to a mix of change of fund managers and redemptions. Miton in particular has been selling a number of small cap stocks to meet redemptions, so FIPP isn't alone on that front. Happy to continue holding here as I believe the share price recent trend will reverse at some point, although I don't have my crystal ball to hand. |
Posted at 29/2/2024 15:47 by rivaldo Glad to see that FIPP have taken advantage of the recent uptick in Exscientia's share price to offload the rest of their holding.That's another £2.54m in the bank, to recycle into the rest of the portfolio: A £14 million return for a total cost of £2,000 is pretty astonishing. Hopefully the likes of Pulsiv and others will bring in more in terms of capital return even if perhaps not quite as good in percentage terms! |
Posted at 09/2/2024 10:19 by acuere I share your frustration at the lack of news on ustake. The trouble is I’m not fully au fait with how long discussions, testing and product designs take. When we hear they are in talks with majors and then hear nothing for ages we just don’t know if talks are still ongoing or if they walked away. For now I’m happy to accept they are still on track with discussions etc.I’d also add that if I was invested in Pulsiv PLC and they were valued at say £200m then I might be more concerned. But at a value of £50m, which as Fipp share price at 40%+ discount to Nav effectively makes their value £30m I am not concerned. And remember that £50m value is from November 2022. They have made huge progress and strengthened the board since then. The other thing I’d ask is have you spoken to Pulsiv about your concerns? At least 3 posters on here have done. It might provide you with some reassurance. |
Posted at 29/1/2024 10:04 by rivaldo Cheers acuere, excellent news.Here's ST's full tip for FIPP in the IC: "Back future tech winners via Frontier IP Smart technology funds are investing in tile company Alusid ahead of an IPO – and so can you through this below-the-radar investment company January 22, 2024 by Simon Thompson Portfolio attracts high-profile technology investor 50 per cent share price discount to NAV Edinburgh-based Frontier IP (FIPP:40p), a technology investment company that provides commercialisation services to university spin-outs in return for ‘free equity’ stakes, has announced a successful capital raise for portfolio company Alusid. Alusid creates premium-quality tiles and architectural surfaces by recycling industrial waste ceramics, glass and other materials, much of which would end in landfill. As part of a larger £1.13mn funding round, Octopus AIM VCT funds are investing £0.5mn in Alusid, which values the company at £9.5mn. Frontier IP holds a 35.4 per cent equity stake in Alusid worth £3.3mn. The cash proceeds will be used to support Alusid's expansion into new product ranges and territories. For instance, the company is developing hard-wearing floor tiles, which are expected to launch commercially this year, and is in discussions with potential distributors in Scandinavia and Northern Europe. It is also exploring options for an IPO later this year. There is clear momentum in Alusid’s business. In the past year, the company has launched environmentally friendly products with Topps Tiles, the UK's largest tile retailer, and is in collaboration with Imerys, a world leader in speciality minerals, to develop floor tiles. Other customers include H&M, Pret a Manger, BBC and Starbucks. Prospects for further gains on Frontier’s portfolio are being woefully undervalued. To put this into perspective, Frontier holds a liquid £2.3mn stake in Nasdaq-listed Exscientia (US: EXAI)Exscientia (US: EXAI), a clinical-stage pharmaceutical technology company, pro-forma cash of £2.5mn (after factoring in operating expenses in the past six months), a £33mn equity portfolio, £5.9mn of debt investments and £1mn of trade receivables. Ignoring the possibility of valuation uplifts in the forthcoming interim results, the £22.5mn market capitalisation company is rated on a 50 per cent discount to book value. That’s an extreme discount considering the progress being made by multiple investee companies including its largest holding, Plymouth University spin-out Pulsiv Solar, a green technology company that has developed on-chip technology to improve the energy efficiency of power supplies, battery chargers, LED lighting and photovoltaic solar cells. Frontier IP’s 18 per cent stake in Pulsiv had a read-through valuation of £9.3mn following Pulsiv's last fundraising. So, although Frontier IP’s share price is slightly shy of my last buy call (‘Bag a technology bargain buy’, 31 October 2023), there is a clear disconnect between the value embedded in an exciting investment portfolio and the price attributed to its investments by the market. Buy." |
Posted at 02/11/2023 11:10 by rivaldo For the record, here's the IC's new FIPP tip:"Bag a technology bargain buy A 50 per cent discount to NAV is harsh given the operational progress being made by the group’s investee companies NAV falls 6.5 per cent to £45.5mn (81.8p) Cash and listed stake in Exscentia currently worth £6.2mn (11.1p) Progress on multiple investee companies Shares in Edinburgh-based FrontierIP (FIPP:41.5p), a technology investment company that provides commercialisation services to university spin-outs in return for ‘free equity’stakes, dipped 10 per cent post annual results.The fall was caused by an unexpected 6.5 percent (£3.1mn) reversal in net asset value (NAV)after the group booked a £2.2mn unrealised loss on its 17 per cent stake in The Vaccine Group(TVG). TVG is creating a range of vaccines based on a novel herpes virus-based platform to prevent the spread of economically damaging diseases in livestock. The company now has eight vaccine candidates approaching proof of principle. Its most advanced projects are for pigs. During the year, TVG successfully developed a vaccine candidate for streptococcus suis, a bacterial disease carried by pigs that causes productivity losses as well as meningitis and other symptoms in humans. The project was funded by the UK and Chinese governments. In addition to streptococcus suis, TVG has developed a transmissible candidate vaccine against a virus called Lassa fever for use in ratsthat spread the disease. Funded by a US government agency, a small-scale trial showed the candidate could be transmitted between rats,significantly improving their immunity to Lassa fever and reducing its spread between them. The company is in discussions with potential partners.Progress on monetising its technology will be needed to drive TVG’s valuation higher, but that’s not out of the question. It’s something that Plymouth spin-out, green technology company Pulsiv Solar, the group’s largest holding, is already doing. Its on-chip technology not only improves the energy efficiency of power supplies, battery chargers, LED lighting and photovoltaic solar cells, but is proving popular with leading electronic component suppliers around the world looking to exploit the commercial opportunity. A £1.5mn fundraising placed a £50mn pre-money valuation on Pulsiv,which means that Frontier’s 18.2 per cent equity stake has a read-through valuation of £9.4mn,accounting for 28 per cent of its £33mn equity portfolio at the 30 June 2023 financial year-end. The operational progress of harvest robotics developer Fieldwork Robotics, a spin-out from the University of Plymouth, is also attracting investor interest. Post Frontier’s financial year-end, the company secured a £1.5mn investmentfrom Elbow Beach Capital, a decarbonisation,sust It’s a similar positive story at Cambridge University spin-out CamGraPhIC. The company’s graphene-based photonics run at higher speeds and lower temperatures than equivalent technologies – and therefore use less energy. Datacentres, which consume around 1 per cent of global energy output, are one potential marketfor its optical transceivers. Sir Michael Rake,former chair of BT Group(BT.A), invested in CamGraPhIC’s latest funding round, which raised £1.26mn to complete the fabrication and testing of demonstration devices with multinational companies. The technology is starting to gain traction with governmental organisations, too. In the financial year, Frontier booked a £1.4mn gain on its 20.8 per cent stake in CamGraPhIC, in line with the fundraising valuation, and a £0.7mn gain on its £2.6mn loan note holding. Deep discount to sum-of-the-parts valuations Post period end, Frontier IP subscribed for a further £1.3mn of CamGraPhIC loan notes (of which £0.8mn was classified as Advances in the2023 accounts) to accelerate its development.The investment reduces group pro-forma cash to £4.1mn. In addition, Frontier intends to dispose of more shares in Nasdaq-listed Exscientia (US:Exscientia(EXAI) Effectively, the liquid stake in Exscientia and pro-forma cash are worth £6.2mn (11.1p) or a quarter of the group’s market capitalisation of £23mn (41.5p). It means that Frontier’s £33mn(59p) equity portfolio, £5.9mn (10.5p) of debt investments and £1mn (1.8p) of trade receivables are in the share price for 58 per cent less than their combined carrying valuations.That̵ |
Posted at 23/5/2023 13:47 by acuere A lot of the AI pharmas jumped sharply yesterday. Exai presenting at SLAS this week and sentences like this from us,“ We believe that within this decade the design of all new drug candidates will be augmented with AI.” would surely stimulate investors appetite for these stocks. Hopefully Exai can hold these share price gains. Not that it seems to make any difference to Fipp share price Exai are up about 50% this year and yet Fipp over 20% down. I think we need a juicy Pulsiv announcement or confirmation of Allusid IPO to get things moving in the right direction again. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
